Thursday, October 05, 2017 2:09:52 PM
And it includes this gem:
Through patented Glassware 2.0 technology, organizations can tackle their enterprise applications that need modernizing; a market that Microsoft officials have said includes 16 million 'classic' Win32, .NET and Windows Presentation Foundation (WPF) apps in existence.
"We have come a long way over the last couple of years as far as the capabilities of Glassware and the flexibility to deploy this game changing technology", said Peter Bookman, global strategist, Sphere 3D. "The OVA, coupled with the support that the HVE team can provide, customers are ready to tackle just about any application in their ecosystem and deploy it on existing infrastructure".
Read that carefully. Glassware can now deliver, at the end of 2017, legacy Windows apps.
A remarkable achievement considering that in 2013 and throughout 2014 the company claimed it could deliver mainframe, all Windows apps, Apple iOS and OSX, Linux, AIX, Android and of course, Fortran.
PS The announcement says the new Glassware OVA can mount on VMware ESXi hypervisor. As a reminder, that is the same technology that the company claimed Glassware made irrelevant and unnecessary. And even better, ESXi is the same one that Sphere executives said Glassware would make redundant. Remember the Citrix killer?
It would be funny if it wasn't for the fact that people lost millions on this story.
"We are tired of development, now is the time to sell, sell, sell" - Sphere CEO Peter Tassiopoulos, Feb 2014
Recent ANY News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:00:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:31:39 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:22:03 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 11:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 02:54:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/29/2024 10:15:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/26/2024 09:19:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 01:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:30:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:42:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:06:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:03:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 11:58:51 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/05/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:19:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:30:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/03/2024 09:07:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 11:01:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 11:01:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:44:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:43:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/05/2023 09:37:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:21:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 01:04:52 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/17/2023 10:59:03 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM